A Cancer Vaccine Made for One Patient at a Time Shows Promise Against Melanoma

What if doctors could take a sample of your cancer, study its unique genetic makeup, and create a vaccine designed specifically to help your immune system recognize and destroy any cancer cells left behind?

That’s the idea behind an experimental treatment developed by Merck and Moderna. And new clinical trial results suggest it could become an important advance in treating melanoma, one of the most dangerous forms of skin cancer.

The treatment, called intismeran autogene, is made individually for each patient using genetic information from that person’s tumor.

Unlike vaccines given to healthy people to prevent infections, this one is administered after cancer has already been diagnosed and surgically removed. Its purpose is to help prevent the disease from returning.

In a major clinical trial involving more than 1,100 patients, the personalized treatment combined with Merck’s immunotherapy drug Keytruda significantly reduced the risk of melanoma recurrence compared with Keytruda alone.

The results are encouraging, but the treatment has not yet received FDA approval.

And while the technology is attracting attention as a breakthrough, personalized cancer treatment has a longer history than many people realize.

Personalized Cancer Vaccines Aren’t Entirely New

On April 29, 2010, the U.S. Food and Drug Administration approved Provenge, a treatment for certain men with advanced prostate cancer.

Provenge, also known as sipuleucel-T, was a milestone because it used a patient’s own immune cells to fight cancer.

Doctors collected immune cells from the patient’s blood, processed them in a laboratory to stimulate a response against prostate cancer, and returned them through an infusion.

Clinical trials showed that patients receiving Provenge lived approximately four months longer, on average, than those receiving a comparison treatment.

Despite that success, Provenge never became a widely used cancer treatment. Its specialized manufacturing process, cost, and limited eligibility hindered adoption.

The treatment remains FDA-approved for a specific group of patients with metastatic prostate cancer that no longer responds to hormone therapy.

Now, 16 years later, researchers are pursuing a different way to tailor cancer treatment to the individual.

Instead of collecting and modifying a patient’s immune cells, the new approach uses genetic information from the tumor itself to design a treatment.

How a Vaccine Can Be Designed for One Person

Every cancer develops through genetic changes that allow abnormal cells to grow and spread.

Some of those mutations produce unusual proteins that distinguish cancer cells from healthy cells.

Researchers believe those differences can become targets for the immune system.

To create intismeran, scientists analyze genetic material from a patient’s tumor and compare it with normal tissue.

Computer software identifies mutations likely to produce proteins the immune system can recognize.

Researchers then select up to 34 of those targets and create a strand of messenger RNA, commonly called mRNA, that contains instructions for producing them.

The personalized mRNA is packaged in tiny particles and administered to the patient.

Once inside the body, cells use the instructions to make the selected proteins. Those proteins are then presented to the immune system, helping it recognize what to attack.

The process is somewhat like giving the immune system a collection of identifying photographs.

The goal is to train immune cells to recognize and attack cancer cells carrying those mutations, including cells that may remain after surgery.

Every patient’s vaccine is different.

A treatment made for one person’s tumor cannot simply be given to another patient.

New Trial Results Show a Significant Difference

Merck and Moderna announced on August 19, 2026, that their Phase 3 clinical trial had met its primary goals.

At the time, the companies did not release detailed figures.

Those numbers became available in October, when researchers presented the results at the European Society for Medical Oncology Congress.

The study, known as INTerpath-001, involved 1,137 patients with stage IIB through IV melanoma whose tumors had been surgically removed.

Patients were randomly assigned to receive either Keytruda alone or Keytruda combined with the personalized mRNA treatment.

Keytruda, whose generic name is pembrolizumab, is an established immunotherapy drug that helps the immune system recognize and attack cancer cells.

The new treatment was designed to strengthen that response.

After two years, researchers reported the following results:

• 82.2% of patients receiving the personalized vaccine plus Keytruda were alive without cancer recurrence.
• 70% of patients receiving Keytruda alone were alive without cancer recurrence.

That represents a 12.2-percentage-point difference between the two groups.

Across the study period, the combination treatment reduced the relative risk of recurrence or death by 42%.

Researchers also found a 38% reduction in the relative risk of distant cancer spread or death.

These findings represent the first successful Phase 3 trial of an individualized mRNA cancer treatment.

However, the results do not mean the vaccine cures melanoma or eliminates the possibility of recurrence.

The study also has not yet established whether patients receiving the combination ultimately live longer.

Researchers will continue following participants to answer that question.

University of Virginia Researcher Sees an Important Advance

The findings have attracted attention from cancer researchers at the University of Virginia.

Dr. Craig Slingluff, a UVA Health surgical oncologist who directs the university’s Human Immune Therapy Center, has spent more than three decades studying cancer vaccines.

In an October 26 interview published by UVA Today, Slingluff described the findings as a significant advance in melanoma treatment and personalized cancer therapy.

He explained that the approach builds on two major scientific developments: genetic sequencing and mRNA technology.

The technology makes it possible to identify targets unique to a patient’s tumor and train immune cells to recognize them.

Slingluff also emphasized that the new vaccine is designed to prevent cancer from recurring or spreading after treatment.

It is not intended to prevent someone from developing melanoma in the first place.

Researchers hope similar approaches could eventually help against other cancers.

There Are Still Challenges to Overcome

Despite the promising results, personalized cancer vaccines still face practical challenges.

Each treatment must be manufactured separately.

That requires obtaining a suitable tumor sample, analyzing the cancer’s mutations, selecting potential immune targets, and producing the customized mRNA.

The process can take weeks.

Slingluff noted that about 20% of patients enrolled in the melanoma trial could not receive the personalized vaccine, mainly because insufficient tumor material was available.

Manufacturing time and cost could also affect how easily the treatment becomes available outside research settings.

Safety remains another consideration.

In the trial, both groups experienced treatment-related side effects. Patients receiving the personalized vaccine frequently experienced fever, injection-site pain, and fatigue.

Serious treatment-related side effects were reported in 14.2% of patients receiving the combination, compared with 13.4% receiving Keytruda alone.

The overall safety results did not reveal unexpected concerns, but continued monitoring will be necessary.

Could This Approach Work Against Other Cancers?

Researchers are already investigating intismeran for other cancers.

Clinical studies include non-small cell lung cancer, bladder cancer, and kidney cancer.

The National Cancer Institute lists several ongoing studies evaluating the technology in different treatment settings.

However, success against melanoma does not guarantee the same results for other cancers.

Different tumors have different genetic mutations, immune responses, and treatment challenges.

Each cancer type will require its own clinical evidence.

UVA researchers are also exploring cancer vaccines that target proteins shared by many patients’ tumors, rather than requiring an entirely new treatment for each individual.

That approach could potentially make vaccines available more quickly.

A New Chapter in a Long History

The idea of using the immune system to fight cancer has occupied researchers for decades.

Provenge demonstrated in 2010 that an individually manufactured immune treatment could gain FDA approval and extend survival for some patients.

Now, the Merck-Moderna trial offers strong evidence that a vaccine designed around a patient’s tumor genetic mutations can improve outcomes when combined with an existing immunotherapy.

It’s an important development, but not yet an available cure.

Merck and Moderna are discussing the results with regulators, and the treatment remains under investigation.

For patients with high-risk melanoma, the findings offer hope that doctors may eventually have another way to reduce the chances of cancer returning after surgery.

And for researchers, the larger possibility is just as compelling.

Instead of relying entirely on medicines designed for thousands of patients, cancer treatment may increasingly include therapies created for the unique biology of one person’s disease.